A carbidopa/levodopa tablet formulation (Dhivy) designed to facilitate dose adjustment is now available for the treatment of Parkinson’s disease, postencephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. It is the first and only carbidopa/levodopa tablet designed to be divided for precise dosing.
The table is supplied as a functionally scored tablet containing 25 mg of carbidopa and 100 mg of levodopa. Each tablet has three scores with each segment containing 6.25 mg of carbidopa and 25 mg of levodopa. Tablets can be broken at the score lines if a patient has difficulty swallowing it due to its size.
Dhivy is a product of Alora Pharmaceuticals. Consult product labeling for full prescribing information.
